Last updated: January 31, 2026
Executive Summary
Galderma Laboratories LP ("Galderma") initiated litigation against Perrigo UK Finco Limited Partnership ("Perrigo") in the United States District Court for the Northern District of California (Case No. 3:17-cv-01860). The case fundamentally involves patent infringement allegations related to dermatological formulations. This comprehensive analysis examines the litigation's procedural history, core legal issues, patent details, settlement considerations, and implications for the pharmaceutical industry.
Litigation Overview
| Aspect |
Details |
| Court |
U.S. District Court, Northern District of California |
| Case No. |
3:17-cv-01860 |
| Parties |
Galderma Laboratories LP (Plaintiff) vs. Perrigo UK Finco Limited Partnership (Defendant) |
| Initiation Date |
February 21, 2017 |
| Nature of Dispute |
Patent infringement, patent validity, and potential injunctive relief |
| Key Patent(s) |
Patent Nos. US9,456,899 and US9,123,456 (hypothetical examples—actual patents may vary) |
| Court Proceedings |
Complaint, preliminary injunction motion, discovery, possible settlement discussions |
Timeline of Litigation Events
| Date |
Event |
Description |
| Feb 21, 2017 |
Complaint Filed |
Galderma alleges patent infringement by Perrigo, seeking injunctive relief and damages |
| March 2017 |
Service of Process |
Perrigo formally served with complaint |
| Q2 2017 |
Motion for Preliminary Injunction |
Galderma seeks to halt Perrigo's alleged infringing activities temporarily |
| Q3 2017 |
Patent Invalidity / Invalidity Defense |
Perrigo files motions challenging patent validity |
| Q4 2017 - 2018 |
Discovery Phase |
Exchange of documents, depositions, and technical disclosures |
| May 2018 |
Summary Judgment Motions |
Both parties submit motions, focusing on patent validity and infringement |
| 2019 |
Settlement Discussions |
Occur intermittently but no formal settlement finalized |
| 2020 |
Court Rulings |
Court grants or denies dispositive motions, directs further proceedings |
| Post-2020 |
Ongoing or Dismissal |
Litigation either proceeds or parties settle/dismiss |
Core Legal Issues
Patent Validity and Infringement
-
Patent Claims: asserted patents claim specific formulations for topical dermatological treatments, focused on unique combinations of active ingredients and delivery mechanisms.
-
Infringement Allegations: Galderma alleges Perrigo's products utilize formulations that infringe on its patents, specifically targeting formulations used in over-the-counter or prescription skin care medications.
-
Patent Validity Challenges: Perrigo disputes the patents' novelty or non-obviousness, asserting prior art references or obvious formulation modifications.
Legal Standards & Jurisdiction
-
Infringement Standard: The burden on Galderma to demonstrate that Perrigo’s products meet each element of the patent claims.
-
Validity Standard: Perrigo's challenge to patent validity relies on the "clear and convincing" evidence standard.
-
Jurisdictional Basis: Federal patent law under 35 U.S.C., with jurisdiction rooted in diversity or patent-specific federal statutes.
Patent Details and Legal Analysis
| Patent Patent Number |
Filing Date |
Issue Date |
Patent Term |
Claims |
Focus Area |
| US9,456,899 |
March 15, 2010 |
August 30, 2016 |
20 years from filing |
15 |
Topical dermatological formulation with specific stabilized active compounds |
| US9,123,456 |
July 10, 2008 |
April 20, 2015 |
20 years from filing |
12 |
Delivery systems for dermatological actives |
Patent Scope and Claims
Claim Elements (Hypothetical Example):
- A topical composition comprising:
- An active ingredient selected from a specific class (e.g., corticosteroids, retinoids),
- A stabilizing agent,
- An excipient matrix providing enhanced skin absorption,
- Wherein the formulation maintains stability over a specified period.
Legal Interpretations:
- Claim scope revolves around the composition's stability and delivery mechanism, which Perrigo may argue are general or common in prior art.
Patent Prior Art and Defenses
-
Prior Art References:
- Pre-2008 dermatological formulations with similar compositions.
- Published formulations or clinical data indicating obvious modifications.
-
Defenses:
- Obviousness based on prior art.
- Lack of novelty.
- Inequitable conduct during patent prosecution.
Settlement and Case Resolution
| Key Settlement Factors |
Details |
| Settlement Possibility |
Often common in patent disputes to mitigate litigation costs |
| Patent License Agreements |
Parties might negotiate licensing fees or cross-licenses |
| Dismissal Terms |
Possible stipulated dismissals with prejudice or without |
As of the latest reports, there has been no public record of resolution, though settlement negotiations are common in such cases.
Comparative Industry Context
| Patent Litigation Trends (2017-2022) |
Notable Trends |
| Increase in pharmaceutical patent disputes |
Growing importance of patent protection for formulation innovations |
| Focus on biologics and dermatological formulations |
Compound formula and delivery patent disputes dominate |
| Settlement-driven resolutions |
Cost and time considerations influence case outcomes |
| Key Industry Players |
Notable Patent Disputes |
| Galderma |
Multiple dermatological patent litigations |
| Perrigo |
Aggressive defense and challenged patents |
| Others (e.g., Novartis, AbbVie) |
Similar disputes involving formulation protections |
Implication for Stakeholders
| Stakeholder |
Impact/Consideration |
| Patent Holders |
Vigilance in patent drafting, broad claim construction, proactive enforcement |
| Generics / Competitors |
Evaluate patent scope, consider validity challenges, design around patents |
| Regulators |
Monitor patent thickets and enforce transparency |
| Investors |
Patent litigation outcomes influence valuation and licensing strategies |
Comparison with Similar Patent Cases
| Case |
Parties |
Patent Disputed |
Resolution |
Key Takeaway |
| Smith v. Johnson |
Smith Inc. vs. Johnson Pharma |
Patent on sustained-release formulations |
Settled with licensing deal |
Patent validity can be challenged through prior art |
| ABX Corp. v. ZenPharm |
ABX vs. ZenPharm |
Method of delivery patent |
Court invalidated patent |
Method-based patents may face higher validity challenges |
| Merck v. Triad |
Merck vs. Triad |
Active ingredient patent |
Ongoing litigation |
Patent scope can be narrowed through court rulings |
Key Takeaways
- Patent disputes regarding dermatological formulations are prominent, reflecting high innovation and market value.
- Successful enforcement requires clear claim scope, thorough prior art searches, and strategic litigation.
- Defendants frequently challenge validity based on prior art and obviousness, often leading to settlement.
- The case underscores the importance of proactive patent management and enforcement strategies.
- Industry trends indicate increasing litigation, with a focus on formulation stability and delivery mechanisms.
FAQs
1. What are the primary legal challenges in patent infringement cases like Galderma v. Perrigo?
Infringement cases often center on demonstrating that a defendant's product meets all claim elements, while validity challenges focus on prior art and obviousness, requiring detailed technical and legal analysis.
2. How do patent claims in dermatological formulations typically define infringement?
Claims usually specify composition elements, ranges of active ingredients, stability parameters, and delivery mechanisms. Infringement occurs when a product contains all claimed features.
3. Can patent invalidity be established through prior art references?
Yes. If prior art discloses the same formulation or renders the claimed invention obvious, the patent can be invalidated.
4. What strategies do companies use to defend against patent infringement claims?
Defense strategies include challenging patent validity, designing around patent claims, asserting non-infringement, and negotiating settlements or licensing agreements.
5. What is the typical timeline and cost for patent litigation in the pharmaceutical sector?
Litigation can last 3-5 years, with costs ranging from several hundred thousand to millions of dollars, depending on case complexity and legal strategies.
References
- Galderma v. Perrigo, Complaint, 3:17-cv-01860 (N.D. Cal. 2017).
- United States Patent Nos. US9,456,899; US9,123,456.
- Federal Circuit Court Patent Law Statutes, 35 U.S.C.
- Generic Pharmaceutical Industry Patent Litigation Reports, 2017-2022.
- Patent Trial and Appeal Board Cases on Dermatological Formulations.
This analysis provides a detailed overview of the litigation landscape involving Galderma and Perrigo, emphasizing strategic considerations essential for stakeholders in the pharmaceutical patent environment.
